DURAVYU Durability: A Phase-3 Data Bet with Asymmetric Upside for EYPT
EyePoint (EYPT) is priced like a development-stage story despite a large market cap and thin revenue. DURAVYU's sustained-release profile and upcoming Phase 3 topline readout for wet AMD in mid-2026 create a clear catalyst. This trade idea outlines an actionable long with entry, stop, and target, and discusses the balance between clinical binary ri…